DNLI (Denali Therapeutics Inc.) Stock Market Reviews

crown

search

Read and share opinions on DNLI (Denali Therapeutics Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

DNLI

Denali Therapeutics Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results
Nov 11, 2025
Denali Therapeutics (DNLI): Exploring Valuation After Recent Share Price Rebound
Nov 10, 2025
Denali Therapeutics Announces Board and Executive Leadership Updates
Nov 6, 2025
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
Oct 13, 2025
Denali Therapeutics (DNLI): Evaluating Valuation Disconnect Despite Lack of Major News
Sep 29, 2025
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
Sep 10, 2025
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy
Jul 31, 2025
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target
Jul 16, 2025
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
Jul 7, 2025
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
Jun 5, 2025

Reviews